Development of an HPLC-MS/MS Method to Determine Janagliflozin in Human Plasma and Urine: Application in Clinical Study.

Ling Song,Yang Liu,Xueting Yao,Hongzhong Liu,Bo Chen,Xifeng Ma,Huimin Zhou,Chengkon Shih,Ji Jiang,Xijing Chen,Pei Hu,Dongyang Liu
DOI: https://doi.org/10.4155/bio-2018-0129
IF: 2.695
2018-01-01
Bioanalysis
Abstract:Aim: Janagliflozin is a novel, orally selective sodium-glucose co-transporter-2 (SGLT2) inhibitor, which showed good efficacy and safety in preclinical study. The objective of this study is to develop and validate the HPLC–MS/MS method to determine janagliflozin in both of human urine and plasma. Methods: Janagliflozin was separated on Waters Xbridge Phenyl C18 column and detected on API 4000 tandem mass spectrometer with ESI source in negative mode. Results: This method provided good linearity in the range of 5–5000 ng/ml and 5–1000 ng/ml in plasma and urine. The matrix effect and extraction recoveries across three concentration levels were consistent. Conclusion: This validated method is reliable and has been successfully applied to a first-in-human trial of janagliflozin in Chinese subjects.
What problem does this paper attempt to address?